阿托莫西汀
哌醋甲酯
注意缺陷多动障碍
执行职能
心理学
神经心理学
认知灵活性
工作记忆
随机对照试验
医学
精神科
临床心理学
听力学
认知
内科学
作者
Chi-Shin Wu,Chi-Yung Shang,Hsiang-Yuan Lin,Susan Shur-Fen Gau
出处
期刊:Journal of Child and Adolescent Psychopharmacology
[Mary Ann Liebert]
日期:2021-04-01
卷期号:31 (3): 187-196
被引量:9
标识
DOI:10.1089/cap.2020.0146
摘要
Objectives: This study aimed to compare the efficacy of methylphenidate and atomoxetine on improving executive functions among children with attention-deficit/hyperactivity disorder (ADHD). Methods: This was an open-label, head-to-head, 3-month, randomized clinical trial with two-arm parallel-treatment groups: osmotic-release oral system methylphenidate (OROS-MPH; n = 79) and atomoxetine once daily (n = 78). Three major domains of executive functions were assessed, including response selection/inhibition, flexibility, and planning/working memory. The neuropsychological measures included the Conners' continuous performance test and the Cambridge Neuropsychological Test Automated Battery. Results: We found that both treatment groups showed improvement in executive functions (p-value <0.05 for the major indices of each domain). In addition, OROS-MPH was associated with a greater magnitude of improvement in the response selection/inhibition; the slope for detectability improvement in the Conners' continuous performance test was 0.06 for atomoxetine and 0.15 for OROS-MPH (p-value <0.01); the slope in rapid visual information processing was 2.22 for atomoxetine and 3.45 for OROS-MPH (p-value <0.05). Conclusion: Both OROS-MPH and atomoxetine improved various domains of executive functions in children with ADHD. There is greater improvement in response selection/inhibition among patients treated with OROS-MPH than those with atomoxetine. This trial was registered with ClinicalTrials.gov (no. NCT00916786).
科研通智能强力驱动
Strongly Powered by AbleSci AI